Eyestem Research

We are delighted to announce completion of all nine patient injections for our phase one trial of Eyecyte-RPE? to treat Geographic Atrophy secondary to Dry Age related Macular Degeneration. Interim results show promise and will be explored further in our upcoming phase two trial in India and the US. Key takeaways: 1. No Serious Adverse Events reported in any of the nine patients. 2. Average improvement of 14.9 letters in ETDRS standard vision tests reported in six patients over a 3-6 month follow up. 3. Signs of disease reversal observed in some patients. 4. Structural/anatomical changes corresponding to vision rescue identified in almost all patients post 3 months. About Eyecyte-RPE? Eyecyte-RPE?, derived from induced pluripotent stem cells (hiPSCs) is a proprietary retinal cell therapy product with a novel composition, developed and patented by Eyestem Research. The product can help replace the damaged or lost retinal pigment epithelium (RPE) cells and provide crucial support to the adjoining photoreceptor layer. This unique formulation is allogeneic, scalable and can be stored as a frozen vial for long periods of time. For more information, please visit https://lnkd.in/gkReKH7d

We are delighted to announce approval from our Drug Safety Monitoring Board (DSMB) to move forward with the third cohort of patients for our phase one trial to treat Geographic Atrophy secondary to Dry AMD. So far, the first two cohorts have had no Serious Adverse Events (SAEs) and some mild Treatment Emergent Adverse Events (TEAEs) thus reinforcing the safety profile of Eyecyte-RPE. We now move forward with the third and final cohort of the phase one trial. Exciting times !

Glad to share a recent video that we have made to explain to non-scientists/ non-clinicians what we do and how we hope to make an impact. Hope it is useful.

We are delighted to announce interim results for our first in human trial for Geographic Atrophy secondary to Dry AMD. 1. Eyecyte-RPE was well tolerated across the first two doses with no serious adverse events (SAEs) and minimal Treatment Emergent Adverse Events (TEAEs). 2. Five out of Six patients had a improvement in vision (3-31 letters). At this time, improvement has been sustained at five months for the first two enrolled patients. 3. Noticeable decrease in RPE defect area and Photoreceptor defect area was observed in the injected eye vs. the uninjected eye. 4. Structural changes in OCT observed at the area of injection corroborated the functional improvements. The excellent safety profile, along with promising signs of efficacy, will be further explored in our phase two study. Taken together, this data represents a large and critical inflection point for Eyestem in bringing this therapy to patients who need it the most !

This is a fantastic exhaustive list of all iPSC derived clinical trials. Glad to see us on the list of course ! Thanks to the authors for creating such a valuable resource Agnete Kirkeby Heather Main Melissa Carpenter

Super proud to have our Founder and CEO, Jogin Desai, feted with the "Entrepreneur of the Year" Award at the BioSpectrum Asia Excellence Awards in Singapore !

Excited to announce our recent patent filing for a customized Sub-retinal injection delivery technique which can be used, among others, to safely deliver Eyecyte-RPE into the area of interest for treatment of Geographic Atrophy (GA). The USP of this technique is its ability to harness readily available instruments used frequently in the operating room and integrate them together in a sometimes counter intuitive yet effective way ! With this invention, we move one step closer to create a safe, effective therapy for GA which can be adapted by surgeons worldwide with relative ease.

We are delighted to announce approval from our Drug Safety Monitoring Board (DSMB) to move forward with the second cohort of patients for our phase one trial to treat Geographic Atrophy secondary to Dry AMD. In the words of our Principal Investigators "We are truly excited to see the excellent safety profile of Eyecyte-RPE and early indications of efficacy lead us to believe that this therapy has the potential to be transformational for patients. We look forward to recruiting the second cohort of patients and are excited to be part of the team that brings such innovative therapies closer to patients that need it most.” Download the press release for more details

Today is a high water mark for all of us working at Eyestem Research. With the first three patient injections, we are one crucial step closer to our long term vision of creating a scalable cell therapy platform for incurable diseases-starting with the largest cause of incurable blindness for people over 50 globally. While it is early days, we are hoping Eyecyte-RPE can transform lives of patients suffering from this terrible disease- both in India and abroad. Taslimarif Saiyed, PhD Dr. Ramesh Byrapaneni Ashish Ranjan, Ph.DGert Hoogland Oppel Greeff Gillian Corken Suresh Ramu Raja Narayanan Raghu Gullapalli

We are beyond thrilled to announce completion of the first round of patient injections for our first in human trials to treat Geographic Atrophy, secondary to Dry Age-related Macular Degeneration. For those tuning in recently, Eyecyte-RPE is a patented RPE cell suspension designed to arrest and potentially reverse vision loss due to Dry AMD- the largest cause of incurable blindness for people above 50 globally. Completing the first 3 patient injections represents a critical milestone for our quest to find a cure. A special thanks to our exceptionally skilled surgeons at participating sites, whose dedication and attention to detail make all the difference ! Endiya Partners Centre for Cellular and Molecular Platforms (C-CAMP) DBT BIRAC Kotak Alternate Asset Managers Limited L V Prasad Eye Institute (LVPEI) https://lnkd.in/e7yH_RaU